RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:

RT @Adrian_H
Just got served in the $SAVA Cassava v Bredt lawsuit while at my poster discussing Simufilam science and binding at the #ctad22 conference.

#scienceintegrity

http://www.Simuflimflam.com

Unfortunately had to leave at this point to catch my flight home to EU.

It is a pitty, that this important panel discussion is scheduled on the very last day of the conference.

#CTAD22 #Alzheimer

personal takeaways:
M. Tartaglia: who are the caregivers: the daughters / daughters in law. Example: CDR - we know that this endpoint is differently answered by male and female.

Call of actions:
P. Ferrell - lets make this priority. It is priority for our patients, for the loved ones. however, needs to be much broader priority. We have a community that are counting on us.

#CTAD22 #Alzheimer

some personal takeaways:
If gender issues are well integrated this means usually that other underrepresented groups are better integrated - set of techniques are the same.
H. Snyder - men are more getting their care at home, female in the community. We need to understand how diagnostics work in all populations in the clinical practise. How can we ensure that the tools we are providing are also inclusive for sex/gender/sexual identifications.
#CTAD22 #Alzheimer

RT @cumplido_irene@twitter.com

Today I am presenting my poster about brain age, AD and sex differences at CTAD!
Join me in P100 to learn more about it #CTAD22 #BarcelonaBeta @fpmaragall@twitter.com

🐦🔗: https://twitter.com/cumplido_irene/status/1598379541214670849

#Alzheimer #CTAD22 round table - where are we in 2030?

P. Scheltens: will see many more therapies - also small molecules. Screening will be important. Biomarkes may become so good, that we may measure that 10 years in advance.

H. Fillit: 75% in the pipeline are not amyloid/tau targeted and I hope that some may succeed, hope to see advances. Combination therapies. This may extent to antiinflammatory drugs - the same way than cancer developments.

#CTAD22 round table:
Remarkable statement by H. Fillit (#Alzheimer Drug Discovery Foundation, NY):

Lets go to the 80s - if we dont have a RR cuff, there had not been development of antihypertensives. Biomarkers are important. We have to go beyond Amyloid and Tau, into inflammation as well.

Have the blood biomarkers gone fare enough that we do not need brain scans anymore?
Also can digital tests or retinal screening even have us not need to do CSF, and radiology anymore?

RT @bucklr01@twitter.com

Everyone's talking about the phase 3 results of #Alzheimers drug Lecanemab presented at #CTAD #CTAD22 and published this evening in the @NEJM@twitter.com. But a really striking subgroup analysis that no one else has pointed out yet (cred. @RoreBole@twitter.com) is that the findings are driven by men!

🐦🔗: https://twitter.com/bucklr01/status/1598122092796706817

Christopher C. Rowe - prognostic utility of plasma p217+tau #CTAD22 #Alzheimer
- 153 cognitively unimpaired and 50 cognitively impaired
- Compared MMSE and CDR-SB p217+tau level, metaT tau PET, amyloid PET
- Results: p217+tau predicted change in MMSE, CDR-SB with effect comparable to Abeta centiloid and tauMetaT SUVR
- can get by in #Alzheimer studies without Amyloid PET and save probably costs.
- `smale study - 50 patients only. needs replication

Summary Trial 3 #brexpiprazole 2 or 3mg associated with statist. signif. greater improvement vs. placebo in primary and key secondary efficacy endpoints in #Alzheimers #CTAD22

#Agitation in Alzheimer’s Dementia: #Brexpiprazole phase III trial- George Grossberg #CTAD22
previous trials https://www.sciencedirect.com/science/article/pii/S1064748119305214
Trial 3: use of 2mg and 3mg
- Design: randomized 2:1 2mg oder 3mg vs. Placebo
- Results: 2 or 3mg significant improvement
- Safety: AE - similar rates than placebo, sedation, extrapyramidal disorders, falls - only few reported on that, 3mg higher rate on discontinuation - no consistant pattern pattern in this group

Within oral discussion #Lecanemab being quoted as eventually less efective in women and younger patients.

van Dyck discusses that: this is a sub group analysis. Are younger patients and women - CDR overlaps. These are forrest plots, so it is not correct if people walk away and think Lecanemab less works with women or younger. #CTAD22 #Alzheimers

#Lecanemab being quoted in subanalysis to be less efective in younger patients and women.

Discussion van Dyck: we have to keep in mind this is sub group analysis (forrest plots). Younger patients and women - CDR overlaps. These are forrest plots, so it is not correct if people walk away and think lecanemab less works with women or younger. While amyloid may be established, still we have to understand much more on amyloid #CTAD22 #Alzheimers

#STOMP-Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD) Pilot Study Results on Central Nervous System Penetrance and Alzheimer’s Disease Biomarkers Mitzi Gonzales #CTAD22 #Alzheimers.
- 12 week intervention study
- n=5 early stage Alzheimer disease
- only 6 adverse events
- CSF IL6, IL23, IL16 upregulation
- Lumipulse CSF - strong trends towards ABeta42
- Quanterix CSF - no significant findings

"It is time to close the book on the amyloid hypothesis", it is one of the conclusions. Good thread.
---
RT @schrag_matthew
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:
https://twitter.com/schrag_matthew/status/1597860167806111744

R/T by @schrag_matthew (neuro/AD expert):

“New Alzheimer’s drug not game changer:
(From neuro MD focused on AD)
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points: 1) This trial is much better than the frustrating data associated with Aducanumab. Demographics are well balanced between groups 2/8

RT @schrag_matthew@twitter.com

My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM@twitter.com. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:

🐦🔗: https://twitter.com/schrag_matthew/status/1597860167806111744

Randall Bateman at #CTAD22 Graduate I and II robust results on benefit-risk profile of gantenerumab in early symtpomatic AD
- did not meed primary endpoint

RT @schrag_matthew@twitter.com

My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM@twitter.com. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points:

🐦🔗: https://twitter.com/schrag_matthew/status/1597860167806111744